Qianhong Pharmaceutical said at an earnings briefing that it
文 / 小金
2026-10-27 12:40:03
来源:亚金网
Qianhong Pharmaceutical said at an earnings briefing that its QHRD106 injection for acute ischemic stroke is in the closing stage of Phase IIb trials. After completing communications with China’s Center for Drug Evaluation (CDE), the company will promptly advance Phase III trials and related marketing-authorization filings.
